Inspire Medical price target lowered to $215 from $300 at Mizuho

Mizuho analyst Anthony Petrone lowered the firm’s price target on Inspire Medical to $215 from $300 and keeps a Buy rating on the shares. The company reported an “uncharacteristic miss” on sales due to a temporary decrease in prior authorizations at the beginning of Q4 due to a pilot program that was later reversed resulting in stabilizing trends exiting the period, the analyst tells investors in a research note. However, the firm believes .the stock selloff move makes for an entry point as GLP-1 fears could be overblown.